Showing results (251-260 of 271) with videos related to

Sort By:
Pageof 28
Antiviral Research|September 10, 1999
Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%I Arany, S K Tyring, M A Stanley, et al.
The Journal of Infectious Diseases|August 11, 1998
A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimodS K Tyring, I Arany, M A Stanley, et al.
The British Journal of Dermatology|December 24, 2013
Generalized verrucosis in a patient with GATA2 deficiencyE S West, M Y Kingsbery, E M Mintz, et al.
Clinical Immunology (Orlando, Fla.)|May 5, 1999
Neutrophilic myeloperoxidase-macrophage interactions perpetuate chronic inflammation associated with experimental arthritisD L Lefkowitz, M P Gelderman, S R Fuhrmann, et al.
The Journal of Investigative Dermatology|February 1, 1996
Recombinant desmoglein 3 has the necessary epitopes to adsorb and induce blister-causing antibodiesO M Memar, S Rajaraman, R Thotakura, et al.
Annals of Surgery|June 1, 1994
Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogeneB M Evers, P L Rady, K Sandoval, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2000
Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital wartsI Arany, S K Tyring, M M Brysk, et al.
Antimicrobial Agents and Chemotherapy|April 29, 1998
Imiquimod, a patient-applied immune-response modifier for treatment of external genital wartsK R Beutner, S K Tyring, K F Trofatter, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1996
Induction of blister-causing antibodies by a recombinant full-length, but not the extracellular, domain of the pemphigus vulgaris antigen (desmoglein 3)O Memar, B Christensen, S Rajaraman, et al.
The Journal of Infectious Diseases|December 1, 1990
Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trialR C Reichman, D Oakes, W Bonnez, et al.
Pageof 28